Coya Therapeutics gets FDA green light for Phase 2 ALS trial with COYA 302

Coya Therapeutics Inc. (NASDAQ: COYA) has received formal acceptance from the U.S. Food and Drug Administration (FDA) for its Investigational New Drug (IND) application for COYA 302, a proprietary dual-immunomodulatory biologic being developed to treat amyotrophic lateral sclerosis (ALS). The clearance allows the Houston-based clinical-stage biotechnology company to initiate a Phase 2, multicenter, double-blind, placebo-controlled trial designed to assess the therapy’s safety and efficacy in ALS patients.

The acceptance also triggers a milestone payment of USD 4.2 million to Coya Therapeutics from its development partner Dr. Reddy’s Laboratories Ltd., as part of a previously disclosed strategic collaboration.

COYA 302 is an investigational subcutaneous therapy that combines low-dose interleukin-2 (LD IL-2) with CTLA-4 Ig, aiming to restore immune balance by enhancing regulatory T cell (Treg) function and suppressing inflammation from activated monocytes and macrophages. The therapy’s dual mechanism is designed to counter the progressive neuroinflammatory pathways that drive ALS pathology.

What does FDA acceptance of COYA 302’s IND signal for the ALS clinical pipeline in 2025?

The FDA’s green light represents a significant advancement in the high-risk, high-reward landscape of ALS drug development. With fewer than a handful of approved ALS treatments on the market—such as Relyvrio (Amylyx), Radicava (Mitsubishi Tanabe), and riluzole—each offering only modest clinical benefit, the entry of novel immunomodulatory approaches is being closely watched by investors and advocacy groups alike.

COYA 302’s IND acceptance enables the company to pursue a statistically powered Phase 2 study that will enroll patients across multiple centers in the United States. The trial aims to generate critical data on the biologic’s ability to slow or halt neurodegeneration in ALS—a disease that currently lacks any curative options. Coya Therapeutics said it expects to begin enrollment “in the near term” and noted that study design parameters include a randomized, double-blind structure with placebo controls to ensure scientific rigor.

How is Coya positioning COYA 302’s immunomodulatory mechanism against ALS progression?

Coya’s development thesis rests on the interplay between regulatory T cells (Tregs) and immune-driven neuroinflammation in ALS patients. Scientific research has shown that impaired Treg function is associated with accelerated disease progression in ALS. COYA 302’s dual-agent formulation is engineered to boost Treg numbers and functionality via LD IL-2, while concurrently dampening excessive immune activation through CTLA-4 Ig—an approach that may achieve additive or synergistic therapeutic outcomes.

According to Coya Therapeutics, the goal is to restore homeostasis in a dysregulated immune environment, thereby mitigating the muscle-wasting and respiratory failure that typically characterize ALS’s terminal phase. The company believes that its biologic platform may also have future applications in other neurodegenerative disorders marked by chronic inflammation, such as multiple sclerosis or Parkinson’s disease.

Why is Dr. Reddy’s Laboratories investing in Coya’s ALS pipeline strategy?

The FDA’s IND clearance also serves as a commercial inflection point, activating a milestone clause in the partnership agreement between Coya Therapeutics and Dr. Reddy’s Laboratories Ltd. Milan Kalawadia, Chief Executive Officer of Dr. Reddy’s North America operations, said the progress validates the “strong scientific and strategic rationale” of the collaboration, adding that the companies are “energized by the potential of moving a step closer to offering a treatment for patients living with ALS.”

The USD 4.2 million payment is expected to support trial initiation costs and ongoing R&D. For Dr. Reddy’s Laboratories, the deal represents a diversification move beyond its traditional generics base and into high-impact biologics targeting rare neurological diseases. This also marks one of the Indian pharmaceutical firm’s more notable U.S.-based clinical co-developments in the neurology space.

How large is the patient population for ALS and what does the current treatment landscape look like?

ALS, also known as Lou Gehrig’s Disease, is a rare but devastating neurodegenerative condition affecting approximately 20,000 individuals in the United States, with roughly 5,000 new diagnoses each year. Characterized by the progressive degeneration of motor neurons in the brain and spinal cord, ALS typically leads to complete muscle paralysis, loss of speech, and respiratory failure within three to five years of symptom onset.

The disease is currently monitored using the Revised ALS Functional Rating Scale (ALSFRS-R), where patients generally lose one point per month on average. Despite recent regulatory approvals, the clinical effectiveness of existing drugs remains limited, and the median survival rate has not significantly improved over the past decade. As such, institutional investors and venture funds have shown renewed interest in early-stage ALS therapies that introduce novel biological mechanisms or precision-targeted delivery.

What has been the stock performance and investor sentiment around Coya Therapeutics in recent months?

Shares of Coya Therapeutics (NASDAQ: COYA) have experienced moderate volatility in 2025, largely in line with expectations for a micro-cap clinical-stage biotech with no approved products. While COYA 302 remains its lead candidate, the broader pipeline includes Treg-targeted therapies for Alzheimer’s disease and frontotemporal dementia—both of which are still in preclinical or early-phase development.

Following the IND acceptance, investor sentiment turned modestly bullish, with COYA shares seeing a pre-market uptick driven by retail volume and small-cap institutional interest. Analysts who track early-stage neurodegenerative drug development emphasized that the FDA’s decision significantly de-risks Coya’s clinical roadmap, especially as it positions the firm to attract further non-dilutive capital or licensing interest.

Despite these tailwinds, analysts also cautioned that the true inflection point will be contingent on positive Phase 2 efficacy data, which could take 12 to 18 months to materialize. Until then, the stock is expected to trade within a speculative biotech risk band, sensitive to both trial updates and broader sector sentiment.

What is the broader outlook for Coya Therapeutics’ biologics platform in neurology?

With regulatory clearance now secured, the focus will shift toward clinical execution and patient enrollment. CEO Arun Swaminathan noted that the IND acceptance marks a “pivotal moment” for the firm, which is preparing to launch its most ambitious trial to date. While ALS remains the immediate priority, Coya Therapeutics has previously disclosed pipeline ambitions across several neuroinflammatory and neurodegenerative disease states, where Treg dysfunction may be implicated.

Coya’s strategy mirrors a broader trend among early-stage biotech firms leveraging immunology-based platforms to address CNS diseases historically underserved by conventional drug classes. If the Phase 2 trial generates compelling efficacy signals, analysts believe the firm could become a serious acquisition target or enter into broader licensing deals with global pharmaceutical partners.